News | July 10, 2023
Thermo Fisher Scientific to acquire CorEvitas for $912.5 million
Advances clinical research capabilities with leading regulatory grade registries platform
Advances clinical research capabilities with leading regulatory grade registries platform
Testing supporting allergy diagnosis now accessible to more people in more communities
Bourgoin early development hub broadens offerings for oral solid dose formulations
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics RoboCell cell line automation platform
Cell sorting technology supports researchers advancing new therapies
Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.
New mass spectrometry instrument and consumables launch during IMSC 2022
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
